Which has stronger earnings and valuation, ACIU or ALVO?

Alvotech has higher revenue and earnings than AC Immune. Alvotech is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $4.31M 53.13 -$85.03M -$0.82 N/A Alvotech $588.90M 1.75 $27.92M -$0.25 N/A

Is ACIU or ALVO more profitable?

Alvotech has a net margin of -14.36% compared to AC Immune's net margin of -1,788.02%. Alvotech's return on equity of -11.92% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% Alvotech -14.36% -11.92% -7.59%

Is ACIU or DBVT more profitable?

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% DBV Technologies -3,506.53% -119.33% -84.43%

AC Immune (ACIU) Competitors

$2.24 -0.01 (-0.44%)

As of 09:49 AM Eastern

Compare

ACIU vs. ALVO, JANX, ANRO, DBVT, and SLDB

Should you buy AC Immune stock or one of its competitors? MarketBeat compares AC Immune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AC Immune include Alvotech (ALVO), Janux Therapeutics (JANX), Alto Neuroscience (ANRO), DBV Technologies (DBVT), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does AC Immune compare to Alvotech?

AC Immune (NASDAQ:ACIU) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

51.4% of AC Immune shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AC Immune has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Alvotech has higher revenue and earnings than AC Immune. Alvotech is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	53.13	-$85.03M	-$0.82	N/A
Alvotech	$588.90M	1.75	$27.92M	-$0.25	N/A

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 233.33%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 122.87%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alvotech has a net margin of -14.36% compared to AC Immune's net margin of -1,788.02%. Alvotech's return on equity of -11.92% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Alvotech	-14.36%	-11.92%	-7.59%

In the previous week, Alvotech had 1 more articles in the media than AC Immune. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for AC Immune. Alvotech's average media sentiment score of 0.53 beat AC Immune's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
AC Immune	Neutral
Alvotech	Positive

Summary

AC Immune and Alvotech tied by winning 8 of the 16 factors compared between the two stocks.

How does AC Immune compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, Janux Therapeutics had 2 more articles in the media than AC Immune. MarketBeat recorded 2 mentions for Janux Therapeutics and 0 mentions for AC Immune. Janux Therapeutics' average media sentiment score of 0.88 beat AC Immune's score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Positive
AC Immune	Neutral

Janux Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Janux Therapeutics' return on equity of -12.93% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
AC Immune	-1,788.02%	-125.26%	-40.85%

Janux Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AC Immune has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	97.87	-$113.62M	-$1.84	N/A
AC Immune	$4.31M	53.13	-$85.03M	-$0.82	N/A

Janux Therapeutics presently has a consensus price target of $38.08, indicating a potential upside of 137.28%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 233.33%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Janux Therapeutics beats AC Immune on 12 of the 16 factors compared between the two stocks.

How does AC Immune compare to Alto Neuroscience?

AC Immune (NASDAQ:ACIU) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Alto Neuroscience had 6 more articles in the media than AC Immune. MarketBeat recorded 6 mentions for Alto Neuroscience and 0 mentions for AC Immune. Alto Neuroscience's average media sentiment score of 0.49 beat AC Immune's score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Overall Sentiment
AC Immune	Neutral
Alto Neuroscience	Neutral

Alto Neuroscience has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Alto Neuroscience's return on equity of -47.22% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Alto Neuroscience	N/A	-47.22%	-38.81%

Alto Neuroscience has lower revenue, but higher earnings than AC Immune. Alto Neuroscience is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	53.13	-$85.03M	-$0.82	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

AC Immune presently has a consensus price target of $7.50, indicating a potential upside of 233.33%. Alto Neuroscience has a consensus price target of $35.25, indicating a potential upside of 35.57%. Given AC Immune's higher probable upside, equities research analysts plainly believe AC Immune is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

AC Immune has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

51.4% of AC Immune shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Alto Neuroscience beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does AC Immune compare to DBV Technologies?

AC Immune (NASDAQ:ACIU) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, DBV Technologies had 19 more articles in the media than AC Immune. MarketBeat recorded 19 mentions for DBV Technologies and 0 mentions for AC Immune. DBV Technologies' average media sentiment score of 0.07 beat AC Immune's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
AC Immune	Neutral
DBV Technologies	Neutral

AC Immune has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, meaning that its share price is 195% less volatile than the broader market.

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 233.33%. DBV Technologies has a consensus target price of $48.50, indicating a potential upside of 232.88%. Given AC Immune's higher possible upside, equities research analysts clearly believe AC Immune is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

AC Immune has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	53.13	-$85.03M	-$0.82	N/A
DBV Technologies	$5.64M	152.96	-$146.95M	-$3.51	N/A

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

DBV Technologies beats AC Immune on 9 of the 17 factors compared between the two stocks.

How does AC Immune compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

AC Immune has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
AC Immune	$4.31M	53.13	-$85.03M	-$0.82	N/A

In the previous week, Solid Biosciences' average media sentiment score of 0.00 equaled AC Immune'saverage media sentiment score.

Company	Overall Sentiment
Solid Biosciences	Neutral
AC Immune	Neutral

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Solid Biosciences has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Solid Biosciences' return on equity of -73.42% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
AC Immune	-1,788.02%	-125.26%	-40.85%

Solid Biosciences currently has a consensus target price of $17.11, suggesting a potential upside of 102.50%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 233.33%. Given AC Immune's higher possible upside, analysts clearly believe AC Immune is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Solid Biosciences and AC Immune tied by winning 7 of the 14 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$223.90M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-2.74	20.49	27.07	23.95
Price / Sales	53.13	300.33	515.72	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	4.17	7.92	10.62	6.14
Net Income	-$85.03M	$23.81M	$3.60B	$331.74M
7 Day Performance	-6.64%	-1.09%	-1.26%	-1.82%
1 Month Performance	-6.25%	2.56%	1.07%	-1.45%
1 Year Performance	8.17%	42.16%	23.63%	16.32%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.2174 of 5 stars	$2.24 -0.4%	$7.50 +234.8%	+8.7%	$227.35M	$4.31M	N/A	140
ALVO Alvotech	4.0148 of 5 stars	$3.27 -3.4%	$7.60 +132.8%	-60.5%	$987.22M	$588.90M	N/A	1,460	Positive News Gap Down
JANX Janux Therapeutics	3.8279 of 5 stars	$15.96 -1.1%	$38.08 +138.6%	-39.2%	$976.29M	$10M	N/A	30	Positive News
ANRO Alto Neuroscience	2.464 of 5 stars	$27.73 -1.1%	$35.25 +27.1%	+835.3%	$976.20M	N/A	N/A	N/A	Analyst Upgrade
DBVT DBV Technologies	3.9641 of 5 stars	$16.32 +2.1%	$48.50 +197.2%	+45.7%	$966.31M	$5.64M	N/A	80	Earnings Report Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. ALVO, JANX, ANRO, DBVT, and SLDB

How does AC Immune compare to Alvotech?

Summary

How does AC Immune compare to Janux Therapeutics?

Summary

How does AC Immune compare to Alto Neuroscience?

Summary

How does AC Immune compare to DBV Technologies?

Summary

How does AC Immune compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. ALVO, JANX, ANRO, DBVT, and SLDB

How does AC Immune compare to Alvotech?

Do insiders & institutionals hold more shares of ACIU or ALVO?

Which has more volatility and risk, ACIU or ALVO?

Which has stronger earnings and valuation, ACIU or ALVO?

Do analysts recommend ACIU or ALVO?

Is ACIU or ALVO more profitable?

Does the media prefer ACIU or ALVO?

Summary

How does AC Immune compare to Janux Therapeutics?

Does the media refer more to JANX or ACIU?

Is JANX or ACIU more profitable?

Which has more volatility & risk, JANX or ACIU?

Do insiders and institutionals have more ownership in JANX or ACIU?

Which has stronger valuation and earnings, JANX or ACIU?

Do analysts recommend JANX or ACIU?

Summary

How does AC Immune compare to Alto Neuroscience?

Does the media favor ACIU or ANRO?

Is ACIU or ANRO more profitable?

Which has preferable earnings and valuation, ACIU or ANRO?

Do analysts rate ACIU or ANRO?

Which has more risk and volatility, ACIU or ANRO?

Do insiders and institutionals believe in ACIU or ANRO?

Summary

How does AC Immune compare to DBV Technologies?

Does the media favor ACIU or DBVT?

Which has more risk & volatility, ACIU or DBVT?

Is ACIU or DBVT more profitable?

Do analysts rate ACIU or DBVT?

Which has better valuation and earnings, ACIU or DBVT?

Do institutionals & insiders believe in ACIU or DBVT?

Summary

How does AC Immune compare to Solid Biosciences?

Which has stronger earnings and valuation, SLDB or ACIU?

Does the media favor SLDB or ACIU?

Do institutionals and insiders have more ownership in SLDB or ACIU?

Which has more risk & volatility, SLDB or ACIU?

Is SLDB or ACIU more profitable?

Do analysts recommend SLDB or ACIU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools